Ligne de temps

Nicolas Escriou
Chercheur(euse) Permanent(e)
01 Jan 2022
publication
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Lire plus21 May 2021
publication
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.
Lire plus01 Jan 2021
publication
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
Lire plus16 Dec 2020
publication
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Lire plus02 Sep 2020
publication
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.
Lire plus10 Apr 2020
04 Jul 2015
11 May 2015
11 May 2015